Akorn Reports Q4 EPS of $0.23

Akorn, Inc. AKRX, a niche generic pharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2010. Consolidated revenue for the fourth quarter of 2010 was $24.0 million, up 32% over the prior year quarter consolidated revenue of $18.2 million. Net income for the fourth quarter of 2010 was $23.7 million, and earnings per share were $0.23 per diluted share compared to a net loss of $(2.6) million and a loss per share of $(0.03) in the prior year quarter.